

REMARKS

Claims 1-8 and 11-24 have been canceled as a result of the restriction requirement. Elected claims 9-10 have also been canceled, and replaced with new claims 25-32. The claim cancellations are made without prejudice to the filing of continuing applications. Claims 25-32 are now pending.

Claims 9-10 stand rejected under 35 U.S.C. § 101 and under § 112, first paragraph. Applicant respectfully traverses the rejection.

As is known to those skilled in the art, HIV is infectious only in humans. Therefore testing in human cell lines, as disclosed by Applicant, is an accepted method for evaluating potential anti-HIV activity. Consequently, the person of ordinary skill in the art would accept Applicant's *in vitro* assays as indicative of *in vivo* activity. The claims, therefore, fully comply with the utility and enablement requirements of the patent statute.

Notwithstanding the above traversal of the § 101 and § 112 rejections, Applicant submits that the rejections are overcome by the new claims. Accordingly, withdrawal of the rejections is respectfully requested.

Allowance of the claims and passage of the case to issue are respectfully solicited. Should the Examiner believe a

discussion of this matter would be helpful, the Examiner is invited to telephone the undersigned at (312) 913-0001.

Respectfully submitted,

**McDonnell Boehnen
Hulbert & Berghoff LLP**
300 South Wacker Drive
Chicago, Illinois 60606
Telephone: (312) 913-0001

Date: April 29, 2004

By: Raafat Shaltout
Raafat Shaltout
Reg. No. 45,092